ESMC (Escalon Medical) 3-Year EBITDA Growth Rate: 26.00% (As of Mar. 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ESMC Escalon Medical Corp ESMC
34 GF Score
Price $0.19
GF Value $0.15
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Escalon Medical 3-Year EBITDA Growth Rate?

Escalon Medical ESMC 34 3-Year EBITDA Growth Rate is 26.00% as of Mar. 2026, which is at its 10-year median of 26.00. GuruFocus rates ESMC with a GF Score™ of 34/100 and a GF Value™ of $0.15 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 693 Medical Devices & Instruments companies, Escalon Medical ranks better than 73.3% on this metric.

Escalon Medical's EBITDA per Share for the three months ended in Mar. 2026 was $0.16.

During the past 12 months, Escalon Medical's average EBITDA Per Share Growth Rate was 98.30% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 26.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Escalon Medical was 93.90% per year. The lowest was -264.50% per year. And the median was 26.00% per year.


Escalon Medical  (OTCPK:ESMC) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Escalon Medical 3-Year EBITDA Growth Rate Related Terms


ESMC vs NUMD, AEMD, AMIX: 3-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, Escalon Medical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Escalon Medical 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Escalon Medical's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Escalon Medical's 3-Year EBITDA Growth Rate falls into.


ESMC
34GF Score
Escalon Medical Corp ESMC
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Escalon Medical 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 26.00% mean?
Escalon Medical (ESMC) has a 3-Year EBITDA Growth Rate of 26.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Escalon Medical and its competitors. This is near median its historical median of 26.00. According to the industry distribution chart, Escalon Medical ranks #185 out of 693 companies in the Medical Devices & Instruments industry, placing it in the top 26.7%.
Is Escalon Medical's 3-Year EBITDA Growth Rate too high?
Escalon Medical's current 3-Year EBITDA Growth Rate of 26.00% is near median its 10-year median of 26.00. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Escalon Medical's value of 26.00% is 221% above this industry median. Based on the distribution chart, Escalon Medical ranks #185 out of 693 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Escalon Medical has a GF Score™ of 34/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Escalon Medical's 3-Year EBITDA Growth Rate compare to NUMD and AEMD?
According to the Medical Devices & Instruments industry distribution chart, Escalon Medical ranks #185 out of 693 companies for 3-Year EBITDA Growth Rate. This puts Escalon Medical in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. Escalon Medical's value of 26.00% is 221% above this benchmark. While the company's 10-year median is 26.00 vs. the industry median of 8.10, Escalon Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 693 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Escalon Medical's current 3-Year EBITDA Growth Rate of 26.00% is 221% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Escalon Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Escalon Medical's current 3-Year EBITDA Growth Rate is 26.00%, which is near median its own 10-year median of 26.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Escalon Medical stock overvalued right now?
Based on GuruFocus' analysis, Escalon Medical (ESMC) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.19 — trading 23.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 26.00%, which is near median its 10-year median of 26.00 and 221% above the Medical Devices & Instruments industry median of 8.10. Escalon Medical's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Escalon Medical (ESMC), the current 3-Year EBITDA Growth Rate is 26.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Escalon Medical (ESMC) Overvalued in 2026?

Based on GuruFocus' analysis, Escalon Medical stock appears to be overvalued. The current stock price of $0.19 is trading 23.3% above its estimated GF Value™ of $0.15. GuruFocus considers Escalon Medical to be Modestly Overvalued.

Key valuation signals for ESMC:

  • 3-Year EBITDA Growth Rate: 26.00% (near median its 10-year median of 26.00)
  • GF Value™: $0.15 vs. price of $0.19 (23.3% above fair value)
  • GF Score™: 34/100 with 3 warning signs
  • Industry Position: 221% above the Medical Devices & Instruments median (#185 of 693)

No single metric tells the full story. See the ESMC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Escalon Medical Business Description

Address 435 Devon Park Drive, Suite 824, Wayne, PA, USA, 19087
Escalon Medical Corp operates in the healthcare market, specializing in the development, manufacture, marketing, and distribution of medical devices and pharmaceuticals in the area of ophthalmology. Its products are A-Scans, B-Scans, UBM, Pachymeters, Ispan Intraocular Gases, Surgical Packs, Viscous Fluid Transfer Systems, and AXIS Image Management. Substantial revenue is generated from the domestic sales of products.
34GF Score

Get the complete analysis for ESMC

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19
Price
$0.15
GF Value